[📢Efficacy of the STC-1010, a new allogeneic cancer vaccine in different colorectal cancer models #AACR24]
DOWNLOAD PR [📢𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 #𝗔𝗔𝗖𝗥𝟮𝟬𝟮𝟰] Brenus Pharma 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗲𝗱 𝘁𝗼𝗱𝗮𝘆 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗮𝗻𝗱 𝗿𝗼𝗯𝘂𝘀𝘁 𝗮𝗻𝘁𝗶-𝘁𝘂𝗺𝗼𝗿 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝗳𝗼𝗿 𝗦𝗧𝗖-𝟭𝟬𝟭𝟬, 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆, during the Association Cancer Research Annual meeting in San Diego. This is validating our innovative approach to fight #resistant hashtag#tumors and highlighting STC-1010’s potential in clinical trials for treating colorectal cancer ; second leading cause of cancer-death worldwide. An excellent consistency was observed with the 3 latest STC-1010 batches manufactured through standardized and scalable Brenus’ Stimulated-Tumor-Cell (STC) platform production. 🔎“𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝗼𝗳 𝘁𝗵𝗲 𝗦𝗧𝗖-𝟭𝟬𝟭𝟬 𝗮 𝗻𝗲𝘄 𝗮𝗹𝗹𝗼𝗴𝗲𝗻𝗲𝗶𝗰 𝗰𝗮𝗻𝗰𝗲𝗿 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝗶𝗻 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗰𝗼𝗹𝗼𝗿𝗲𝗰𝘁𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 𝗺𝗼𝗱𝗲𝗹𝘀” | Abstract 5003 https://lnkd.in/eibXkXpb Meet George Alzeeb Innovation Manager – 𝘗𝘩𝘋 𝘪𝘯 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺 April 9, 2024, 9:00 AM – 12:30 PM (Pacific Daylight Time) 📍Section 39. Poster available here : https://lnkd.in/ei55Wurf STC doesn’t just fight cancer as it is today; it anticipates how cancer will evolve tomorrow, training the patient’s immune system to recognize and destroy tumors, even as they change. We are building a strong portfolio in solid tumors, leveraging our patented STC platform, leading the path to a new generation of immunotherapies to change a paradigm in oncology. #BrenusPharma #ColorectalCancer #Immunotherapy #STC1010
[📢Brenus awarded French Biotech of the year 2024 🏆🎉]
DOWNLOAD PR Bringing the trophy home 🏆🎉 Awarded by France Biotech last night, we are proud to bring back the cup to Lyon this morning and thank our wonderful team and strong partners for their passion and determination to accelerate innovation in oncology. 👏France Biotech: YOU ROCK ! Congratulations for building and coordinating the French #HealthTech ecosystem ! Your support is essential to drive us in the right direction, for patient’s lives. Many thanks again to all the members of an exceptional jury co-chaired by Lise ALTER, president of AIS (Health Innovation Agency), and Audrey Derveloy, president of Sanofi France Congratulations to the 3 finalist companies in our #Biotech category, honored to be surronded by such impressive nominees : Bioadhesive Ophthalmics ; SparingVision ; VECT-HORUS S.A.S. and Thierry Hulot, Guillaume LAULHE and Alain Huriez. And very impressed by all the winners in other category : reev Amaury Ciurana, MedSmart Sebastien Lenormand, AVALUN Vincent Poher, Nūmi (ex-MUMilk) Eden Banon-Lagrange , InBrain Pharma Véronique Foutel, Dr, HuntX Pharma Laure Jamot, Orakl Oncology Fanny Jaulin, PhD Diane-Laure Pagès and Chipiron Evan Kervella ! Ramener la coupe à la maison 🏆🎉 Récompensés par France Biotech hier soir, nous sommes fiers de ramener le trophée à Lyon ce matin et de remercier notre merveilleuse équipe et nos solides partenaires pour leur passion et leur détermination à accélérer l’innovation en oncologie ! 👏France Biotech : YOU ROCK ! Félicitations pour la construction de l’écosystème #HealthTech français et pour la coordination ! Votre soutien est essentiel pour nous conduire dans la bonne direction, pour la vie des patients. #Oncology #Innovation #Research #STCPlatform
[📢5M€ to obtain safety and efficacy clinical data in colorectal cancer 🎉]
DOWNLOAD PR 🎉 Brenus Pharma winner of the call for proposals hashtag#FRANCE2030 : 5M€ to obtain safety and efficacy clinical data in colorectal cancer 🎉 Nous sommes fiers d’annoncer que Brenus Pharma a été désignée lauréate de l’appel à projet “Innovations en biothérapies et bioproduction” du programme France 2030. ➡️Ce financement majeur de près de 5 millions d’euros vise à accélérer la bioproduction et l’industrialisation du STC-1010, nouvelle hashtag#immunothérapie cellulaire et vaccinale guidée par hashtag#protéomique mise au point pour aider le système immunitaire à lutter contre les tumeurs résistantes. 🔎Ce soutien financier va ainsi permettre d’obtenir les premières données d’efficacité et de sécurité chez l’Homme, du vaccin visant le cancer colorectal métastatique. (mCRC) 🎯Télécharger le communiqué ici / Dowload press release here https://lnkd.in/ePfkh3qy Cette distinction de l’État et Bpifrance valide notre engagement envers l’innovation et souligne notre rôle dans l’avancement de la recherche française en biothérapie : « Brenus Pharma se distingue par sa plateforme innovante qui génère de nouvelles immunothérapies cellulaires et vaccinales guidées par protéomique. Ces thérapies sont basées sur la reproduction in vitro des signatures protéomiques des tumeurs résistantes. Cette innovation nous permet d’éduquer le système immunitaire des patients à reconnaître et cibler ces mécanismes de résistance qui échappent habituellement à sa surveillance. Nous remercions l’Etat via France 2030 pour ce soutien qui valide l’approche technologique de Brenus et devrait permettre d’accélérer sa mise à disposition aux patients. » déclare Paul Bravetti, directeur général. Merci à hashtag#FRANCE2030 ; Bpifrance pour votre confiance et à tous ceux qui nous ont accompagnés Lyonbiopôle Auvergne-Rhône-Alpes ; MabDesign Network; France Biotech, EFS Plus d’informations sur : france2030.gouv.fr | https://lnkd.in/e-zECrMJ | @SGPI_avenir et www.Bpifrance.fr – www.presse.bpifrance.fr – hashtag#Colorectalcancer hashtag#clinical hashtag#BPIFrance hashtag#cancervacinne hashtag#Biotechnology hashtag#Biotech hashtag#Healthcare
[📢PSCC : Let’s collaborate at the heart of innovation in oncology 🚀]
DOWNLOAD PRESS RELEASE 🚀 Let’s collaborate at the heart of innovation in oncology. 🚀 Thrilled to share that Brenus Pharma is now part of the Paris Saclay Cancer Cluster (PSCC) (PSCC), the first national #Oncocluster! 🌐 We are proud to be part of the national and European oncology innovation ecosystem. By combining PSCC’s strengths and Brenus’ technology, we aim to foster #collaborations and accelerate our shared mission to improve #patient care. ➡️ Excited to contribute to PSCC’s collective ambition in reshaping the future of oncology! 🌍💪 #BrenusPharma #OncologyInnovation #PSCC #NextGenerationEU
[📢Stimulated Tumor Cells (STC) vaccine induces response in colorectal cancer #SITC23]
DOWNLOAD PR 🔬#SITC23 Thrilled to share new results we presented at the Society for Immunotherapy of Cancer (SITC) Congress! 🌎 Many thanks to all contributors, Céline Gongora Corentin Richard Romain Boidot Tanguy Fortin Alban Bessede Yan WANG Italiano Antoine Based on these vaccine characterization and preclinical, in-ovo and ex-vivo efficiency data, STC-1010 treatment will soon be evaluated for the first time in clinical trial in advanced metastatic stage of colorectal cancer in 2024.
[📢Brenus annouces its international scientific committee]
LYON, (FRANCE), June 7th, 2023, – Following the American Society of Clinical Oncology’s, Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow”, the company highlighted its international scientific committee. View PDF
[📢 BRENUS Pharma unveils groundbreaking preclinical results for STC-10101 , a promising new drug candidate targeting Colorectal Cancer & Solid Tumors. #AACR23]
DOWNLOAD PR
[📢 French Blood Establishment (EFS) & Brenus Pharma partner for the GMP production of STC-1010, an innovative therapy against colorectal cancer]
French Blood Establishment (EFS) & Brenus Pharma partner for the GMP production of STC-1010, an innovative therapy against colorectal cancer – DOWNLOAD PR
[📢Pharma announces its Strategic Committee supporting & ensuring its value-creating strategic plan]
DOWNLOAD PRESS RELEASE
[📢Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010]
DOWNLOAD PR Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010.